Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15845649 | 0.88 | ADORA2A (0.44) | ADORA2AADORA2B | |
| SCHEMBL15858051 | 0.84 | ADORA2A (0.49) | ADORA2AADORA2BADORA1KCNH2 | |
| SCHEMBL26113066 | 0.77 | ADORA2A (0.43) | ADORA2APDE10AADORA2B | |
| SCHEMBL19942003 | 0.74 | ADORA2A (0.37) | ADORA2AADORA2BADORA1KCNH2 | |
| SCHEMBL15845581 | 0.74 | ADORA2A (0.46) | ADORA2AADORA2B | |
| SCHEMBL15858961 | 0.73 | ADORA2A (0.43) | ADORA2AADORA1KCNH2 | |
| SCHEMBL26330327 | 0.73 | ADORA2A (0.48) | ADORA2APDE10AADORA2BADORA1 | |
| SCHEMBL15858030 | 0.73 | ADORA2A (0.43) | ADORA2AADORA1KCNH2 | |
| SCHEMBL17897295 | 0.72 | ADORA2A (0.50) | ADORA2AADORA2B | |
| SCHEMBL14843534 | 0.71 | KDM4E (0.38) | PDE10AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676780-B2 | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885PDE10A 509/4885ADORA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.